Advanced Therapy CDMO Resilience offers end-to-end manufacturing for biologics, cell therapies, and aseptic products, enabling a single partner for development through commercialization of complex therapies. This positions you to win multi-year development and manufacturing partnerships with biotech and pharma companies pursuing faster, integrated programs.

North American Scale With 1001-5000 employees and a revenue range of 500 million to 1 billion, Resilience demonstrates scale and financial traction suitable for large, multi-year contracts and capacity commitments, particularly for premium therapies that require robust supply reliability in North America.

End-to-End Lifecycle Capabilities spanning biologics drug substance, cell therapies, and aseptic drug product manufacturing for both small and large molecules support end-to-end collaboration from early development to commercial supply.

Digital Collaboration Resilience uses tools such as Wrike, Spotfire, ANSYS and Autodesk. This presents an opportunity to offer integrated digital project management, data analytics and engineering modeling to shorten timelines and reduce risk across programs.

Market Opportunity The rising demand for complex therapies and outsourcing of manufacturing create strong opportunities for premium North American CDMOs; target large biopharma for long-term partnerships and explore co-development with emerging cell therapy companies.